Objective:

To analyze the rate of weight regain specifically following the cessation of GLP-1 receptor agonist medications for weight management.

Approach:

Key Findings:

• Participants lost an average of 8.3 kg during active treatment, but weight regain was significant post-treatment.
• Weight was regained at a mean rate of 0.4 kg per month post-treatment, with a projected return to baseline weight within 1.7 years, emphasizing the need for ongoing management.
• Weight regain was more pronounced for newer incretin mimetics, with semaglutide or tirzepatide users regaining weight at 0.8 kg per month, indicating a need for careful consideration of treatment duration.
• Cardiometabolic markers improved during treatment but returned to baseline levels within a similar timeframe after cessation, underscoring the transient nature of these benefits.

Interpretation:

The benefits of GLP-1 receptor agonists diminish quickly after treatment cessation, suggesting that long-term use may be necessary to maintain weight loss and associated health benefits, which is crucial for effective obesity management.

Limitations:

• High real-world discontinuation rates of GLP-1 medications due to side effects, cost, or dissatisfaction may limit the generalizability of the findings to broader populations.

Conclusion:

Weight management medications may require long-term use for sustained benefits and should be part of a comprehensive obesity treatment strategy that includes behavioral support to enhance effectiveness.

Sources:

• The British Medical Journal
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.